These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 23981003)

  • 1. Immunotherapeutic potential of CpG oligodeoxynucleotides in veterinary species.
    Manuja A; Manuja BK; Kaushik J; Singha H; Singh RK
    Immunopharmacol Immunotoxicol; 2013 Oct; 35(5):535-44. PubMed ID: 23981003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TLR9 agonists: immune mechanisms and therapeutic potential in domestic animals.
    Mutwiri G
    Vet Immunol Immunopathol; 2012 Jul; 148(1-2):85-9. PubMed ID: 21700345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity.
    Vollmer J; Weeratna RD; Jurk M; Davis HL; Schetter C; Wüllner M; Wader T; Liu M; Kritzler A; Krieg AM
    J Leukoc Biol; 2004 Sep; 76(3):585-93. PubMed ID: 15218053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune mechanisms and therapeutic potential of CpG oligodeoxynucleotides.
    Wilson HL; Dar A; Napper SK; Marianela Lopez A; Babiuk LA; Mutwiri GK
    Int Rev Immunol; 2006; 25(3-4):183-213. PubMed ID: 16818371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation.
    Jurk M; Vollmer J
    BioDrugs; 2007; 21(6):387-401. PubMed ID: 18020622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined CpG and poly I:C stimulation of monocytes results in unique signaling activation not observed with the individual ligands.
    Arsenault RJ; Kogut MH; He H
    Cell Signal; 2013 Nov; 25(11):2246-54. PubMed ID: 23876795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiinfective applications of toll-like receptor 9 agonists.
    Krieg AM
    Proc Am Thorac Soc; 2007 Jul; 4(3):289-94. PubMed ID: 17607015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant properties of CpG oligonucleotides in primates.
    Verthelyi D
    Methods Mol Med; 2006; 127():139-58. PubMed ID: 16988453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Innate immunity at the mucosal surface: role of toll-like receptor 3 and toll-like receptor 9 in cervical epithelial cell responses to microbial pathogens.
    Andersen JM; Al-Khairy D; Ingalls RR
    Biol Reprod; 2006 May; 74(5):824-31. PubMed ID: 16421230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toll-like receptors involved in the response to microbial pathogens: development of agonists for toll-like receptor 9.
    Schetter C; Vollmer J
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):204-10. PubMed ID: 15603254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Augmentation of T(H)-1 type response by immunoactive AT oligonucleotide from lactic acid bacteria via Toll-like receptor 9 signaling.
    Shimosato T; Kitazawa H; Katoh S; Tohno M; Iliev ID; Nagasawa C; Kimura T; Kawai Y; Saito T
    Biochem Biophys Res Commun; 2005 Jan; 326(4):782-7. PubMed ID: 15607737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human monocyte-derived dendritic cells express TLR9 and react directly to the CpG-A oligonucleotide D19.
    Hoene V; Peiser M; Wanner R
    J Leukoc Biol; 2006 Dec; 80(6):1328-36. PubMed ID: 17000899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Common human Toll-like receptor 9 polymorphisms and haplotypes: association with atopy and functional relevance.
    Berghöfer B; Frommer T; König IR; Ziegler A; Chakraborty T; Bein G; Hackstein H
    Clin Exp Allergy; 2005 Sep; 35(9):1147-54. PubMed ID: 16164440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CpG oligodeoxynucleotides as TLR9 agonists: therapeutic applications in cancer.
    Murad YM; Clay TM
    BioDrugs; 2009; 23(6):361-75. PubMed ID: 19894778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CpG oligodeoxynucleotides as TLR9 agonists: therapeutic application in allergy and asthma.
    Gupta GK; Agrawal DK
    BioDrugs; 2010 Aug; 24(4):225-35. PubMed ID: 20623989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bovine toll-like receptor 9: a comparative analysis of molecular structure, function and expression.
    Griebel PJ; Brownlie R; Manuja A; Nichani A; Mookherjee N; Popowych Y; Mutwiri G; Hecker R; Babiuk LA
    Vet Immunol Immunopathol; 2005 Oct; 108(1-2):11-6. PubMed ID: 16098606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-talk between toll-like receptors 5 and 9 on activation of human immune responses.
    Merlo A; Calcaterra C; Mènard S; Balsari A
    J Leukoc Biol; 2007 Sep; 82(3):509-18. PubMed ID: 17586660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors.
    El Andaloussi A; Sonabend AM; Han Y; Lesniak MS
    Glia; 2006 Nov; 54(6):526-35. PubMed ID: 16906541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CpG-DNA as immune response modifier.
    Dalpke AH; Heeg K
    Int J Med Microbiol; 2004 Oct; 294(5):345-54. PubMed ID: 15532993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CpG motifs of bacterial DNA exacerbate colitis of dextran sulfate sodium-treated mice.
    Obermeier F; Dunger N; Deml L; Herfarth H; Schölmerich J; Falk W
    Eur J Immunol; 2002 Jul; 32(7):2084-92. PubMed ID: 12115630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.